高齢者のアルコールの消費と認知症のリスクに関する将来的研究
Kenneth J Mukamal1, Lewis H Kuller, Annette L Fitzpatrick
1Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, 330 Brookline Ave, RO-114, Boston, Mass 02215, USA. kmukamal@caregroup.harvard.edu
JAMA
|March 15, 2003
まとめ
適度なアルコール摂取 (週に1〜6杯) は,高齢者の認知症のリスクを下げる可能性があります. 過剰な飲酒は,特に男性およびAPOE ε4アレルを持つ者において,認知症の確率の増加と関連していました.
科学分野:
- 神経科学は神経科学である.
- エピデミオロジー エピデミオロジー
- ゲロントロジーはゲロントロジーの学科です.
背景:
- アルコールの消費は,高齢者の脳血管系と構造に影響を及ぼします.
- アルコールの摂取量と認知症の発生率の関連性は不明である.
研究 の 目的:
- アルコール消費パターンと高齢者の認知症発症リスクとの関連性を調査する.
主な方法:
- 心血管健康研究から65歳以上5888人の成人を対象としたネストケース・コントロール研究.
- 認知症の発生率は,神経学的および神経心理学的検査を使用して評価されました.
- アルコール摂取は,磁気共鳴画像 (MRI) と認知テストの前に自己報告された (ビール,ワイン,アルコール) でした.
主要な成果:
- 1週間に1〜6杯のアルコール飲料を摂取すると,禁酒と比較して認知症の確率が54%低下するとの関連がありました (オッズ比 (OR) 0.46;95%CI,0.27-0.77).
- アルコールの摂取量 (週に14杯以上) が高くなったと,認知症の確率が高かった (OR1.22;95%CI,0.60-2.49).
- 重度の飲酒による認知症のリスクの増加は,男性およびアポリポプロテインE epsilon4アレルを持つ個体においてより顕著でした.
結論:
- 週1回の適度なアルコール摂取 (1〜6杯) は,高齢者のインシデント認知症のリスクの低下と関連しています.
- この発見は,アルコールの消費と認知症リスクの潜在的J型曲線を示唆しています.
関連する概念動画
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...


